{"title":"CD19 negative diffuse large B-cell lymphoma presenting in leukemic phase","authors":"Thulasi Raman Ramalingam, Ragavi Uthayasuriyan, Vikram Prabhakar, Lakshman Vaidhyanathan","doi":"10.1002/cyto.b.22109","DOIUrl":null,"url":null,"abstract":"Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkins lymphoma affecting elderly individuals. It is an aggressive disease, but the outcomes have quite improved after the addition of monoclonal antibodies to the chemotherapy regimen. DLBCL in leukemic phase (L-DLBCL) is extremely rare compared with other mature B cell neoplasms. L-DLBCL can mimic acute lymphoblastic leukemia and immunophenotyping (IPT)","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":"104 4","pages":"331-333"},"PeriodicalIF":2.3000,"publicationDate":"2022-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytometry Part B: Clinical Cytometry","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cyto.b.22109","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 1
Abstract
Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkins lymphoma affecting elderly individuals. It is an aggressive disease, but the outcomes have quite improved after the addition of monoclonal antibodies to the chemotherapy regimen. DLBCL in leukemic phase (L-DLBCL) is extremely rare compared with other mature B cell neoplasms. L-DLBCL can mimic acute lymphoblastic leukemia and immunophenotyping (IPT)
期刊介绍：
Cytometry Part B: Clinical Cytometry features original research reports, in-depth reviews and special issues that directly relate to and palpably impact clinical flow, mass and image-based cytometry. These may include clinical and translational investigations important in the diagnostic, prognostic and therapeutic management of patients. Thus, we welcome research papers from various disciplines related [but not limited to] hematopathologists, hematologists, immunologists and cell biologists with clinically relevant and innovative studies investigating individual-cell analytics and/or separations. In addition to the types of papers indicated above, we also welcome Letters to the Editor, describing case reports or important medical or technical topics relevant to our readership without the length and depth of a full original report.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
